The Plasma Therapy Market size was estimated at USD 2.8 billion in 2023 and is projected to reach USD 5.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.00% during the forecast period (2024-2030).

Plasma Therapy Market

Market Summary

The plasma therapy market is a rapidly evolving segment within the biotechnology industry, focused on utilizing blood plasma and its derivatives for therapeutic purposes. This market encompasses a range of treatments derived from human plasma, including immunoglobulins, albumin, clotting factors, and hyperimmune globulins, which are critical for managing various medical conditions. The growing prevalence of immunodeficiency disorders, neurological diseases, and bleeding disorders is a significant factor propelling the demand for plasma-derived therapies. Additionally, the increased application of plasma therapy in regenerative medicine and wound healing is expanding its scope beyond traditional uses. The market is characterized by a robust collection infrastructure, with plasma donation centers playing a pivotal role in ensuring a steady supply of source material. Leading biotechnology and pharmaceutical companies are heavily invested in research to develop novel plasma-based products and improve purification technologies. The regulatory landscape is stringent, ensuring the safety and efficacy of these biological products, which are often administered in clinical settings. The convergence of advanced biotechnology and increasing healthcare expenditure is fostering a conducive environment for market growth, making plasma therapy a vital component of modern therapeutic solutions.

Key Highlights

The plasma therapy market is distinguished by several key highlights that underscore its strategic importance. A primary highlight is the critical role of plasma-derived immunoglobulins in treating primary and secondary immunodeficiency diseases, providing passive immunity to patients. The market has witnessed significant advancements in pathogen reduction technologies, enhancing the safety profile of plasma products by minimizing the risk of transfusion-transmitted infections. Another notable aspect is the expansion of applications into autoimmune disorders and neurology, with intravenous immunoglobulin (IVIG) being used for conditions like Guillain-Barr? syndrome and chronic inflammatory demyelinating polyneuropathy. The industry is also marked by a high degree of consolidation, with a few major players dominating the global supply chain, ensuring consistent quality and availability. Strategic partnerships between plasma collection organizations and biopharmaceutical companies are common, facilitating efficient raw material sourcing and product development. Furthermore, the emergence of recombinant alternatives to certain plasma-derived factors is influencing market dynamics, though plasma-based therapies remain irreplaceable for many indications due to their complex composition. The increasing geriatric population, susceptible to conditions requiring plasma therapy, further accentuates the market's growth trajectory.

Drivers, Opportunities & Restraints

The growth of the plasma therapy market is driven by several factors, including the rising global incidence of chronic and rare diseases that are treatable with plasma-derived products. The increasing awareness and diagnosis of immunodeficiency disorders, hemophilia, and alpha-1 antitrypsin deficiency are significant drivers, creating a sustained demand for these therapies. Technological advancements in plasma collection and fractionation processes have improved yield and efficiency, supporting market expansion. Opportunities abound in the development of new therapeutic indications for existing plasma products and the exploration of plasma components in emerging fields like regenerative medicine. The growing healthcare infrastructure in developing regions presents a substantial opportunity for market penetration and growth. However, the market faces restraints such as the high cost of therapy and complex manufacturing processes, which can limit accessibility. Stringent regulatory requirements for product approval and plasma donor eligibility criteria pose challenges to rapid market scaling. Additionally, the risk of supply shortages due to dependency on voluntary plasma donations and the ethical concerns surrounding paid donation systems in some regions are notable restraints. Economic fluctuations and reimbursement issues in various healthcare systems can also impact market growth.

Concentration Insights

The plasma therapy market exhibits a high concentration in terms of both geographic presence and key players. A limited number of large-scale companies, such as CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, and Octapharma, dominate the global market. These companies have vertically integrated operations, encompassing plasma collection networks, state-of-the-art fractionation facilities, and extensive research and development capabilities. This concentration is a result of the significant capital investment required for establishing plasma collection centers and fractionation plants, as well as the complex regulatory hurdles that new entrants must overcome. Geographically, North America, particularly the United States, is a major hub for plasma collection and consumption, accounting for a substantial portion of the global supply. Europe is another significant market, with well-established healthcare systems supporting the use of plasma therapies. The Asia-Pacific region is experiencing rapid growth, driven by increasing healthcare expenditure and rising awareness of plasma-derived treatments. This concentrated nature ensures product quality and supply chain reliability but also creates barriers for smaller companies aiming to enter the market.

Type Insights

The plasma therapy market is segmented based on the type of product derived from human plasma. Key product types include immunoglobulins, which are antibodies used to treat immune deficiencies and autoimmune diseases; albumin, employed for volume expansion in shock and burn patients; clotting factors, essential for managing bleeding disorders like hemophilia; and hyperimmune globulins, which are specific antibodies used for conditions such as rabies or tetanus exposure. Immunoglobulins represent the largest segment due to their broad application across multiple therapeutic areas. Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are widely used formulations. Albumin is another significant segment, critical in critical care and surgical settings. The clotting factors segment is vital for hemophilia patients, with factor VIII and factor IX being prominent products. Hyperimmune globulins, though a smaller segment, are crucial for providing immediate immunity against specific pathogens. Each product type requires specialized processing and purification techniques, contributing to the complexity and value of the plasma therapy market. Ongoing research focuses on developing new plasma-derived products and improving the purity and efficacy of existing ones.

Application Insights

Plasma therapy finds application across a diverse range of medical conditions, primarily in hematology, immunology, neurology, and critical care. In hematology, clotting factors derived from plasma are lifesaving for patients with hemophilia and other bleeding disorders. In immunology, immunoglobulins are used to treat primary immunodeficiencies, where the body cannot produce sufficient antibodies, and secondary immunodeficiencies caused by other diseases or treatments. Neurological applications include the use of IVIG for autoimmune neurological disorders such as myasthenia gravis and multifocal motor neuropathy. In critical care, albumin is administered for fluid resuscitation in patients with hypovolemia, burns, or sepsis. Another growing application is in the field of transplant medicine, where immunoglobulins are used to prevent rejection. Additionally, hyperimmune globulins are applied for prophylaxis following exposure to specific infectious agents like hepatitis B or varicella-zoster virus. The versatility of plasma-derived products makes them indispensable in modern medicine, addressing both common and rare conditions. Research continues to explore new therapeutic applications, potentially expanding the market further into areas like oncology and regenerative therapies.

Regional Insights

The plasma therapy market demonstrates distinct regional dynamics influenced by healthcare infrastructure, regulatory policies, and prevalence of target diseases. North America, led by the United States, is the largest market due to its well-established plasma collection ecosystem, high healthcare expenditure, and early adoption of advanced therapies. The region has a high number of plasma donation centers and fractionation facilities. Europe follows, with countries like Germany, France, and the UK being major consumers, supported by favorable reimbursement policies and strong healthcare systems. The Asia-Pacific region is identified as the fastest-growing market, driven by improving healthcare access, rising disposable incomes, and increasing awareness of plasma-derived treatments. Countries such as China, Japan, and Australia are key contributors to growth in this region. Latin America and the Middle East and Africa are emerging markets, with growth potential hampered by challenges in plasma collection infrastructure and economic constraints. However, initiatives to establish local fractionation plants and improve regulatory frameworks are underway in these regions. Overall, regional insights highlight a market that is global yet unevenly developed, with significant opportunities for expansion in emerging economies.

Company Insights

The competitive landscape of the plasma therapy market is dominated by a few key players who have established strong footholds through extensive research, manufacturing capabilities, and plasma collection networks. CSL Limited, through its subsidiary CSL Behring, is a global leader, offering a wide portfolio of plasma-derived therapies for immunology, hematology, and respiratory diseases. Grifols, S.A. is another major player with a significant presence in plasma collection and fractionation, providing products for a range of therapeutic areas. Takeda Pharmaceutical Company Limited, following its acquisition of Shire, has a robust plasma-derived therapy business, particularly in immunology and hematology. Octapharma AG is a prominent privately-owned company specializing in human proteins from human plasma and human cell lines. Kedrion S.p.A. and BioProduct Laboratory are also important players focusing on plasma-derived products. These companies invest heavily in plasma donation centers, often located in regions with favorable donor populations, to secure a steady supply of raw material. Strategic initiatives include mergers and acquisitions, expansion of fractionation capacity, and development of new plasma-derived products to maintain competitive advantage and address unmet medical needs.

Recent Developments

The plasma therapy market has witnessed several recent developments that reflect its dynamic nature and ongoing innovation. Companies are increasingly investing in the expansion of their plasma collection networks to mitigate supply constraints and meet growing demand. For instance, leading players have announced the opening of new plasma donation centers in strategic locations. There is a heightened focus on technological advancements in pathogen inactivation and purification processes to enhance product safety and yield. Research and development efforts are directed towards expanding the therapeutic indications of existing plasma products, with clinical trials exploring new uses in areas like Alzheimer's disease and oncology. Regulatory approvals for new plasma-derived products or for extended indications of existing products have been a key trend, facilitating market growth. Additionally, the market has seen strategic collaborations and partnerships between plasma therapy companies and research institutions to foster innovation. The COVID-19 pandemic also brought attention to convalescent plasma as a potential treatment, although its use has been specific and not universally adopted. These developments indicate a market that is responsive to medical needs and technological possibilities, continuously evolving to improve patient outcomes.

Report Segmentation

This comprehensive market research report on the plasma therapy market provides a detailed analysis segmented by various parameters to offer a granular understanding of the industry. The report is segmented by product type, encompassing immunoglobulins, albumin, clotting factors, and hyperimmune globulins, each analyzed for their market dynamics and growth prospects. Application segmentation covers key areas such as immunology, hematology, neurology, critical care, and others, detailing the usage and demand across different medical fields. The report also includes segmentation by end-user, including hospitals, clinics, and research institutes, highlighting where these therapies are primarily administered or utilized. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, with each region examined for its unique drivers, challenges, and opportunities. This multi-faceted segmentation allows stakeholders to identify specific growth pockets, understand competitive landscapes, and make informed strategic decisions. The analysis within each segment is supported by trends, regulatory impacts, and technological advancements, providing a holistic view of the plasma therapy market.

FAQs

What is plasma therapy used for?

Plasma therapy is primarily used for treating a variety of medical conditions including immunodeficiency disorders, bleeding disorders like hemophilia, neurological diseases, and certain infectious diseases. It involves administering plasma-derived products such as immunoglobulins, clotting factors, or albumin to patients.

How does plasma therapy work?

Plasma therapy works by providing patients with essential proteins or antibodies derived from donated human plasma. For example, immunoglobulins help boost the immune system in immunodeficient patients, while clotting factors aid in blood coagulation for hemophilia patients, effectively replacing missing or deficient components.

What are the risks of plasma therapy?

The risks associated with plasma therapy include potential allergic reactions, transmission of infectious agents despite rigorous screening and pathogen inactivation processes, and side effects like headaches, fever, or chills. However, stringent safety protocols minimize these risks significantly.

Who can donate plasma for plasma therapy?

Plasma donors are typically healthy adults who meet specific eligibility criteria, including age and weight requirements, and pass thorough health screenings and medical history evaluations. Donors must be free from transmissible diseases to ensure the safety of the plasma supply.

How is plasma collected for therapy?

Plasma is collected through a process called plasmapheresis, where blood is drawn from a donor, the plasma is separated from the blood cells, and the remaining blood components are returned to the donor. This process allows for more frequent donations compared to whole blood donation.

What is the difference between plasma therapy and blood transfusion?

Plasma therapy involves the administration of specific components derived from plasma, such as immunoglobulins or clotting factors, targeted for particular deficiencies. A blood transfusion typically involves transferring whole blood or specific blood components like red blood cells or platelets for general support, not solely plasma-derived proteins.

Citius Research has developed a research report titled “Plasma Therapy Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030” delivering key insights regarding business intelligence and providing concrete business strategies to clients in the form of a detailed syndicated report. The report details out the factors such as business environment, industry trend, growth opportunities, competition, pricing, global and regional market analysis, and other market related factors.

Details included in the report for the years 2024 through 2030

• Plasma Therapy Market Potential
• Segment-wise breakup
• Compounded annual growth rate (CAGR) for the next 6 years
• Key customers and their preferences
• Market share of major players and their competitive strength
• Existing competition in the market
• Price trend analysis
• Key trend analysis
• Market entry strategies
• Market opportunity insights

The report focuses on the drivers, restraints, opportunities, and challenges in the market based on various factors geographically. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The Plasma Therapy Market report is segmented on the basis of various market segments and their analysis, both in terms of value and volume, for each region for the period under consideration.

Plasma Therapy Market Segmentation

Regions Covered

• North America
• Latin America
• Europe
• MENA
• Asia Pacific
• Sub-Saharan Africa and
• Australasia

Plasma Therapy Market Analysis

The report covers below mentioned analysis, but is not limited to:

• Overview of Plasma Therapy Market
• Research Methodology
• Executive Summary
• Market Dynamics of Plasma Therapy Market
  • Driving Factors
  • Restraints
  • Opportunities
• Global Market Status and Forecast by Segment A
• Global Market Status and Forecast by Segment B
• Global Market Status and Forecast by Segment C
• Global Market Status and Forecast by Regions
• Upstream and Downstream Market Analysis of Plasma Therapy Market
• Cost and Gross Margin Analysis of Plasma Therapy Market
• Plasma Therapy Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030
  • Competition Landscape
  • Market Share of Major Players
• Key Recommendations

The “Plasma Therapy Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030” report helps the clients to take business decisions and to understand strategies of major players in the industry. The report delivers the market driven results supported by a mix of primary and secondary research. The report provides the results triangulated through authentic sources and upon conducting thorough primary interviews with the industry experts. The report includes the results on the areas where the client can focus and create point of parity and develop a competitive edge, based on real-time data results.

Plasma Therapy Market Key Stakeholders

Below are the key stakeholders for the Plasma Therapy Market:

• Manufacturers
• Distributors/Traders/Wholesalers
• Material/Component Manufacturers
• Industry Associations
• Downstream vendors

Plasma Therapy Market Report Scope

COVID-19 Impact Analysis

Like most other markets, the outbreak of COVID-19 had an unfavorable impact on the Plasma Therapy Market worldwide. This report discusses in detail the disruptions experienced by the market, the impact on flow of raw materials, manufacturing operations, production trends, consumer demand and the projected future of this market post pandemic.

The report has helped our clients:

• To describe and forecast the Plasma Therapy Market size, on the basis of various segmentations and geography, in terms of value and volume
• To measure the changing needs of customers/industries
• To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the market
• To gain competitive intelligence and uncover new opportunities
• To analyse opportunities in the market for stakeholders by identifying high-growth segments in Plasma Therapy Market
• To strategically profile key players and provide details of the current competitive landscape
• To analyse strategic approaches adopted by players in the market, such as product launches and developments, acquisitions, collaborations, contracts, expansions, and partnerships

Report Customization

Citius Research provides free customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Frequently Asked Questions